ArticleFrontiers in oncology2026
Case Report: The role of BRAF mutation in adjuvant and neoadjuvant treatment of melanoma patients: what is the optimal approach?
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While the benefit of adjuvant therapy is well established in patients with stage IIIB Case presentation: We report the clinical case of a patient with cutaneous melanoma initially diagnosed as stage IIIA, harboring BRAF V600E mutation, who did not receive any adjuvant therapy and developed locoregional recurrence within one year from diagnosis. The patient was subsequently treated with anti-PD-1 neoadjuvant immunotherapy but experienced disease progression at both local and distant sites. Then, targeted therapy was initiated, leading to a rapid clinical and radiological improvement. Conclusion: Despite significant advances in the treatment of stage III melanoma, both in the adjuvant and, more recently, neoadjuvant settings, some patient subgroups require more tailored approaches. In particular, the presence of BRAF V600 mutation may indicate a more aggressive disease and identify patients who could benefit more from targeted therapy or combined immune checkpoint inhibition than from anti-PD-1 monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.